Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy

NCT: NCT06965452 · RECRUITING

NCT IDNCT06965452
StatusRECRUITING
Start Date2025-08-12
Completion2027-08-01
SponsorNorthwell Health (OTHER)
First posted
Last updated

Brief Summary

This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.

Frequently Asked Questions

What is Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy?

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy is a clinical trial registered under NCT06965452. Current status: RECRUITING.

What is the status of NCT06965452?

The current status of NCT06965452 (Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy) is: RECRUITING.

When did Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy start?

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy started on 2025-08-12.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑